Symbolic illustration of a woman overcoming heavy menstrual bleeding with elagolix, showcasing renewed uterine health.

Battling Heavy Periods and Fibroids: Is Elagolix the Answer?

Mira Elwood monogram
Mira Elwood in Health & Wellness October 2026 • 4 min read.

"Explore how Elagolix, with and without add-back therapy, offers new hope for women struggling with heavy menstrual bleeding and uterine leiomyomas, enhancing their quality of life."


Heavy menstrual bleeding, often linked to uterine leiomyomas (fibroids), can significantly disrupt a woman's life. These benign tumors, fueled by estrogen and progesterone, affect a large number of women, leading to prolonged, heavy periods, anemia, pelvic pain, and reduced quality of life. Traditional treatments range from surgery to hormonal birth control, but many have limitations, especially for long-term use.

Elagolix, an oral medication, has emerged as a promising alternative. It works by blocking the gonadotropin-releasing hormone (GnRH) receptor, which in turn lowers estrogen and progesterone levels. This reduction can help manage heavy bleeding, but it also raises concerns about potential bone mineral density loss due to lower estrogen.

A recent study investigated the effectiveness and safety of elagolix, both alone and with 'add-back' hormone therapy (estradiol and norethindrone acetate), in women experiencing heavy menstrual bleeding related to uterine leiomyomas. The study aimed to determine if elagolix could reduce bleeding and whether add-back therapy could minimize side effects like bone density loss.

AI Search Multiple angles on this topic

Fibroid-Related Heavy Bleeding

Uterine fibroids are hormone-responsive growths associated with heavy menstrual bleeding. A report on two trials found that premenopausal women with fibroids who received oral elagolix had a significantly lower risk of heavy menstrual bleeding. The provided sources do not give population-level prevalence or impact statistics, so they do not support a broader estimate of how many people are affected.

Elagolix: A New Hope for Managing Heavy Bleeding?

Symbolic illustration of a woman overcoming heavy menstrual bleeding with elagolix, showcasing renewed uterine health.

The study, a double-blind, randomized, placebo-controlled trial, involved premenopausal women with heavy menstrual bleeding (more than 80 mL per month) and uterine leiomyomas. Participants were divided into groups receiving either elagolix alone, elagolix with add-back therapy (different doses of estradiol and norethindrone acetate), or a placebo. The primary goal was to assess the percentage of women achieving a significant reduction in menstrual blood loss (less than 80 mL) by the end of the treatment period.

The results showed that elagolix, both with and without add-back therapy, significantly reduced menstrual blood loss compared to the placebo. Specifically, a large percentage of women in the elagolix groups experienced a substantial reduction in bleeding. The add-back therapy also played a crucial role in mitigating the impact of elagolix on bone mineral density.

  • Significant Reduction in Bleeding: Elagolix, with and without add-back therapy, markedly decreased menstrual blood loss.
  • Bone Density Protection: Add-back therapy helped counteract bone mineral density loss associated with elagolix alone.
  • Improved Quality of Life: Participants in the elagolix groups reported significant improvements in their overall quality of life and reduced symptom severity.
  • Comparable Efficacy: The 300-mg twice-daily and 600-mg daily elagolix doses showed similar efficacy in reducing bleeding and uterine volume.
AI Search Multiple angles on this topic

Limits in Risk Estimates and Trial Outcomes

A limitation of the model-informed approach to extending elagolix treatment is its assumption that the uterine fibroid trial population’s race, BMI, and smoking status reflect the wider patient population. Those factors were used in calculating 10-year fracture risk, so limited representativeness may affect how broadly the estimate applies. The NEJM trial’s primary endpoint also depended on both menstrual blood loss below 80 ml in the final treatment month and at least a 50% reduction from baseline; missing data were handled using multiple imputation.

Efficacy Compared with Placebo

A systematic review and meta-analysis of four trials involving 869 participants found that elagolix improved the likelihood of menstrual blood loss below 80 ml versus placebo (RR 4.81, 95% CI 2.45–9.45) and of a reduction greater than 50% from baseline (RR 4.87, 95% CI 2.55–9.31); both findings were rated moderate-quality evidence. In a randomized trial, primary-endpoint responder rates were 92% and 90% for elagolix alone in cohorts 1 and 2, compared with 27% and 32% for placebo. The same trial reported responder rates of 85% and 73% with elagolix plus 0.5 mg estradiol/0.1 mg norethindrone acetate, and 79% and 82% with 1.0 mg estradiol/0.5 mg norethindrone acetate. The FDA label reports depression, depressed mood, and/or tearfulness in 3% of ORIAHNN-treated women versus 1% of placebo-treated women in Phase 3 trials UF-1 and UF-2.

While the study highlighted the benefits of elagolix, it also noted some side effects. Hot flushes were a common adverse event in women taking elagolix without add-back therapy. Additionally, there were changes in lipid levels, although these generally returned to baseline after treatment. The study also reported no cases of endometrial hyperplasia or malignancy.

Making Informed Choices

Elagolix presents a significant advancement in managing heavy menstrual bleeding associated with uterine leiomyomas. The option of add-back therapy further enhances its appeal by mitigating potential bone density loss and reducing hot flushes. Women experiencing these challenging conditions now have a more comprehensive range of treatment options to discuss with their healthcare providers, potentially leading to improved health outcomes and a better quality of life. Further studies are warranted to assess long-term outcomes and optimal use strategies, but the initial results are encouraging.

AI Search Multiple angles on this topic

Balancing Bleeding Control and Hypoestrogenism

A 2022 systematic review and meta-analysis examined elagolix for heavy menstrual bleeding associated with uterine fibroids, comparing it with placebo and with estradiol/norethindrone acetate. Its background describes elagolix as effective for this use while noting that it is associated with hypoestrogenism, which may be alleviated by adding estradiol/norethindrone acetate. These sources frame add-back therapy as a way to address that concern, but the provided snippets do not give comparative effect estimates or establish a single best regimen.

A Broader GnRH Antagonist Landscape

A review published June 26, 2026, describes a targeted PubMed/MEDLINE search and review of major guidelines through May 2026 on GnRH antagonists for uterine fibroids and adenomyosis. It covers elagolix, relugolix, and linzagolix, including their pharmacological properties, mechanisms, and clinical evidence. A separate market-analysis listing describes elagolix (Orilissa) market coverage across endometriosis and uterine fibroids, treatment adoption, and the competitive environment in women’s health therapeutics. The provided materials describe these areas of review and market analysis but do not supply a specific forecast or quantified future growth figure.

What the bleeding reductions mean in volume

  • 186.5 to 211.4 mL reduction from baselineAmong participants continuing elagolix with add-back therapy in UF-EXTEND, mean reductions from baseline ranged from 186.5 mL in extension month 1 to 211.4 mL in extension month 6.[1]

Reading the treatment comparisons

The placebo comparisons put the average change in bleeding volume into context: the reported reductions with ORIAHNN contrast with small increases in the placebo groups. These averages describe group-level changes, not the experience of every participant.[2]

The extension results show that average reductions from baseline were still present during the additional treatment period. They do not, by themselves, show how those results would compare with continued elagolix alone.[1]

How the comparisons shape the findings

In UF-EXTEND, comparisons between the combination and elagolix-alone groups were not planned or conducted, apart from assessments of bone mineral density. The extension therefore does not provide a direct group comparison of bleeding outcomes.[1]

A review of oral GnRH antagonists notes that the trial evidence has limited generalizability, does not transparently describe disease-level characteristics, and does not compare these treatments with current alternatives. These constraints make it harder to judge how well trial results predict outcomes in a broader, varied population.[3]

What longer follow-up and broader comparisons could show

  • Would longer follow-up clarify the safety implications of the modest, stable bone mineral density decline described for combination preparations?[3]
  • How well would the reported trial outcomes predict treatment success among people with different disease characteristics, or when compared with current alternative treatments?[3]

Sources

  1. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas (pmc.ncbi.nlm.nih.gov)
  2. These highlights do not include all the information needed to use ORIAHNN safely and effectively. See full prescribing information for ORIAHNN. ORIAHNN ® (elagolix, estradiol, and norethindrone acetat (dailymed.nlm.nih.gov)
  3. Considerations on implementation of the newest treatment for symptomatic uterine fibroids: Oral GnRH antagonists. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Elagolix and how does it help with heavy menstrual bleeding?

Elagolix is an oral medication used to manage heavy menstrual bleeding, often associated with uterine leiomyomas. It functions by blocking the gonadotropin-releasing hormone (GnRH) receptor. This action lowers estrogen and progesterone levels in the body, which in turn reduces heavy bleeding. By reducing these hormone levels, Elagolix helps to manage the excessive bleeding caused by uterine leiomyomas. However, it's important to note that lowering estrogen levels can lead to potential side effects, such as bone mineral density loss, which can be addressed with add-back therapy.

2

What is 'add-back' therapy and why is it used with Elagolix?

'Add-back' therapy involves the use of estradiol and norethindrone acetate in combination with Elagolix. It is used to mitigate the side effects associated with reduced estrogen levels caused by Elagolix, such as bone mineral density loss and hot flushes. While Elagolix effectively lowers estrogen and progesterone to manage heavy bleeding, this reduction can lead to undesirable effects. Add-back therapy helps to restore some of the hormonal balance, providing a more tolerable treatment option that preserves the benefits of Elagolix while minimizing its adverse impacts.

3

How effective is Elagolix in reducing menstrual blood loss, and what were the key findings of the study?

Elagolix is highly effective in reducing menstrual blood loss in women with heavy menstrual bleeding due to uterine leiomyomas. A randomized controlled trial showed that Elagolix, both with and without add-back therapy, significantly reduced menstrual blood loss compared to a placebo. The study's key findings included a substantial reduction in bleeding among women in the Elagolix groups, the mitigation of bone mineral density loss with add-back therapy, and improvements in the participants' overall quality of life. Additionally, the study indicated that different doses of Elagolix (300-mg twice-daily and 600-mg daily) showed similar efficacy in reducing bleeding and uterine volume.

4

What are uterine leiomyomas, and how do they contribute to heavy menstrual bleeding?

Uterine leiomyomas, commonly known as fibroids, are benign tumors in the uterus. These tumors are fueled by estrogen and progesterone, and they affect a large number of women. Uterine leiomyomas contribute to heavy menstrual bleeding by increasing the surface area of the uterine lining, which leads to prolonged and heavier periods. They can also cause other symptoms like anemia, pelvic pain, and a reduced quality of life. Elagolix addresses this issue by reducing estrogen and progesterone levels, thereby shrinking the fibroids and reducing the associated bleeding.

5

What are the side effects associated with Elagolix, and how does 'add-back' therapy help manage them?

Common side effects associated with Elagolix include hot flushes and changes in lipid levels. The hot flushes are primarily experienced by women taking Elagolix without add-back therapy due to the reduced estrogen levels. Add-back therapy, which involves the administration of estradiol and norethindrone acetate, helps manage these side effects by partially restoring hormonal balance. This therapy counteracts bone mineral density loss and reduces the occurrence of hot flushes, making the treatment more tolerable. The lipid level changes generally return to baseline after the treatment is completed. The study reported no cases of endometrial hyperplasia or malignancy.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.